Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
| dc.contributor.author | Reinmuth, N. | |
| dc.contributor.author | Goldman, J. W. | |
| dc.contributor.author | Chen, Y. | |
| dc.contributor.author | Hotta, K. | |
| dc.contributor.author | Statsenko, G. | |
| dc.contributor.author | Hochmair, M. J. | |
| dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
| dc.contributor.author | Ji, J. H. | |
| dc.contributor.author | Garassino, M. C. | |
| dc.contributor.author | Poltoratskiy, A. | |
| dc.contributor.author | Verderame, F. | |
| dc.contributor.author | Havel, L. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | Losonczy, G. | |
| dc.contributor.author | Conev, N. V. | |
| dc.contributor.author | Mann, H. | |
| dc.contributor.author | Chugh, P. | |
| dc.contributor.author | Dalvi, T. B. | |
| dc.contributor.author | Paz-Ares, L. | |
| dc.date.accessioned | 2023-02-21T07:34:46Z | |
| dc.date.available | 2023-02-21T07:34:46Z | |
| dc.identifier.citation | Reinmuth N., Goldman J. W., Chen Y., Hotta K., Statsenko G., Hochmair M. J., ÖZGÜROĞLU M., Ji J. H., Garassino M. C., Poltoratskiy A., et al., "Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN", Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, cilt.33 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_08edf58e-77e9-4c47-9083-882d6d5e88ed | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/185928 | |
| dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/08edf58e-77e9-4c47-9083-882d6d5e88ed/file | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2022.07.1625 | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Tıp | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | Sağlık Bilimleri | |
| dc.title | Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN | |
| dc.type | Bildiri | |
| dc.contributor.department | Asklepios Lung Clin , , | |
| dc.identifier.volume | 33 | |
| dc.contributor.firstauthorID | 4156405 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [1228]